US FDA Urges Generics To Stay Engaged On Metered Dose Inhalers

 
• By Michael McCaughan

As the generic drug industry warily watches another transition process for propellants in metered-dose inhalers, the US FDA is urging companies not to discontinue development because they are afraid of being caught in the switch.

The FDA will work with generic sponsors developing metered-dose inhalers with LGWP propellant. (Shutterstock)
Michael McCaughan

Read more by Michael McCaughan

Michael McCaughan is a founding member of Prevision Policy LLC, a leading provider of regulatory and reimbursement policy analysis for the biopharma industry. He was previously the Editor-In-Chief of The Pink Sheet and remains a contributor to the publication.

More from Generics

More from R&D